Opus Genetics (IRD) Stock: Insider Trades, Congress & Funds

Smart money at a glance

Filings to Nov 14, 2026

Net selling: insiders sold $3.2M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: -$3.2M net
CongressSTOCK Act, 180 days: None
Big funds13F, quarter ended Sep 30, 2026: 1 added, 0 cut
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about IRD filings

Are insiders buying or selling Opus Genetics, Inc. (IRD) stock?

Net selling: insiders sold $3.2M and bought $0 of IRD stock on the open market in the 90 days to Nov 14, 2026, according to SEC Form 4 filings. $177K of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Foundation Fighting Blindness, Inc. (Director), who sold $2.8M. The latest filing was on Nov 5, 2026.

Which members of Congress have traded IRD recently?

None. No member of Congress disclosed a IRD trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this IRD smart-money data?

This summary uses filings available on Nov 14, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

13F: filed up to 45 days late.

Smart money on IRD

Lean long1 source:
- Funds
Lean short1 source:
- Insiders

Top traders
No tracked positions at the last update
Insiders
Lean short3 sales · $277K
1 of 3 on scheduled plans. Form 4 filings.
Congress
No recent politician filings found
Funds
- BlackRock, added +$12.5M, holdings at Sep 30
- BlackRock, added +$12.1M, holdings at Jun 30
Lean long · thin2 added · 0 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Influencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about IRD filings

Are insiders buying or selling Opus Genetics, Inc. (IRD) stock?

Which members of Congress have traded IRD recently?

None. No member of Congress disclosed a IRD trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this IRD smart-money data?

Funds

What funds are doing

2 moves · 6 mo

Buys/Adds$24.7M

Buys/Adds (2)

BR
BlackRock
Q3 2026 13F
$12.5M
added
Signals like this: n=13773, 53% finished lower at D15, median -0.4% vs SPY -0.4%
BR
BlackRock
Q2 2026 13F
$12.1M
added

Unlock everything for $29/month

Unlock for $29/month

Reported Nov 10, 2026

Earnings came in 28.6% below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Nov 10, 2026

Period ending

Sep 30, 2026

Earnings per share

-$0.18-28.57% miss

-$0.14 expected

Revenue

$1.1M

SEC filing

Next report

What the street expects next

Estimates as of Nov 13, 2026

EPS expected

-$0.04

-$0.19 to $0.39

Revenue expected

$8.2M

18 analysts

Last 30 days

1up0down

Analysts raising estimates

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 10, 2026	-$0.18est. -$0.14	-28.57%miss	$1.1MSEC filing	-63.1%from $3.1M
Jun 30, 2026Reported Aug 6, 2026	-$0.14est. -$0.15	+6.67%beat	$755.0KSEC filing	-73.8%from $2.9M
Mar 31, 2026Reported May 12, 2026	-$0.75est. -$0.14	-$0.61miss	$2.2MSEC filing	-50.6%from $4.4M
Dec 31, 2025Reported Feb 25, 2026	-$0.21est. -$0.12	-78.27%miss	$3.9MAlpha Vantage	-10.2%from $4.3M
Sep 30, 2025Reported Nov 12, 2025	-$0.25est. -$0.13	-92.31%miss	$3.1MSEC filing	-20.4%from $3.9M
Jun 30, 2025Reported Aug 13, 2025	-$0.12est. -$0.26	+53.85%beat	$2.9MSEC filing	+159.2%from $1.1M
Mar 31, 2025Reported May 15, 2025	-$0.32est. -$0.34	+5.88%beat	$4.4MSEC filing	+155.4%from $1.7M
Dec 31, 2024Reported Mar 31, 2025	-$1.27est. -$0.05	-$1.22miss	$4.3MAlpha Vantage	+154.4%from $1.7M

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $4.23
High: $4.35
Low: $3.96
Prev close: $4.31
52-wk high: $7.07
52-wk low: $1.70
Mkt cap: $392.4M
ROE: -616.0%
Fwd P/E: 12.0x
Beta: 0.81
P/S: 49.6x
P/B: 10.2x
Profit margin: -1726.7%
Op margin: -777.7%

Dec 2025 to Sep 2026

What it sold, what it cost, what was left.

RevenueProfit

Dec 2025Mar 2026Jun 2026Sep 2026

Income statement, 4 periods, all values in US dollars
USD	Dec 2025	Mar 2026	Jun 2026	Sep 2026
What came in
RevenueTotal revenue	$3.9M	$2.2M	$755.0K	$1.1M
Cost of what it soldCost of revenue	$13.0K	$13.0K	—	—
Gross profit	$3.9M	$2.1M	$755.0K	$1.1M
What it spent
Research and development	$10.4M	$10.6M	$11.2M	$14.5M
Sales and adminSelling, general and administrative	$4.9M	$5.9M	$6.0M	$5.9M
Total operating expenses	$15.3M	$16.5M	$17.2M	$20.4M
What was left
Operating profitOperating income	-$11.5M	-$14.4M	-$16.5M	-$19.2M
Interest on debtInterest expense	$1.4M	$651.0K	$531.0K	$0
Profit before tax	-$16.5M	-$65.5M	-$8.1M	-$46.5M
Net profitNet income	-$16.5M	-$65.5M	-$8.1M	-$46.5M
EBITDAEarnings before interest, tax, depreciation, amortisation	-$15.1M	-$64.9M	-$7.6M	-$46.5M

Technicals

Price structure

This stock's price action is mixed.

Trend

Mixed

55 / 100

RSI 14

65balanced

20D volatility

80%annualized

52-week range

$4.06

$1.70$7.07

20D support

$3.23recent floor

20D resistance

$4.52recent ceiling

Returns

5D +1.4%20D +0.2%60D -0.2%

Price vs moving averages

SMA20 +4.5%SMA50 -9.8%SMA200 -4.6%

Volume pace

0.61xvs prior 20D

Quarter / reported

Earnings per share

Beat or miss

Revenue / income

Revenue vs last year

Sep 30, 2026Nov 10, 2026

-$0.18est. -$0.14

-28.57%

$1.1MSEC filing

-63.1%from $3.1M

Jun 30, 2026Aug 6, 2026

-$0.14est. -$0.15

+6.67%

$755.0KSEC filing

-73.8%from $2.9M

Mar 31, 2026May 12, 2026

-$0.75est. -$0.14

-$0.61

$2.2MSEC filing

-50.6%from $4.4M

Dec 31, 2025Feb 25, 2026

-$0.21est. -$0.12

-78.27%

$3.9MAlpha Vantage

-10.2%from $4.3M

Sep 30, 2025Nov 12, 2025

-$0.25est. -$0.13

-92.31%

$3.1MSEC filing

-20.4%from $3.9M

Jun 30, 2025Aug 13, 2025

-$0.12est. -$0.26

+53.85%

$2.9MSEC filing

+159.2%from $1.1M

Mar 31, 2025May 15, 2025

-$0.32est. -$0.34

+5.88%

$4.4MSEC filing

+155.4%from $1.7M

Dec 31, 2024Mar 31, 2025

-$1.27est. -$0.05

-$1.22

$4.3MAlpha Vantage

+154.4%from $1.7M

Income statement, 4 periods, all values in US dollars
USD	Dec 2025	Mar 2026	Jun 2026	Sep 2026
What came in
RevenueTotal revenue	$3.9M	$2.2M	$755.0K	$1.1M
Cost of what it soldCost of revenue	$13.0K	$13.0K	—	—
Gross profit	$3.9M	$2.1M	$755.0K	$1.1M
What it spent
Research and development	$10.4M	$10.6M	$11.2M	$14.5M
Sales and adminSelling, general and administrative	$4.9M	$5.9M	$6.0M	$5.9M
Total operating expenses	$15.3M	$16.5M	$17.2M	$20.4M
What was left
Operating profitOperating income	-$11.5M	-$14.4M	-$16.5M	-$19.2M
Interest on debtInterest expense	$1.4M	$651.0K	$531.0K	$0
Profit before tax	-$16.5M	-$65.5M	-$8.1M	-$46.5M
Net profitNet income	-$16.5M	-$65.5M	-$8.1M	-$46.5M
EBITDAEarnings before interest, tax, depreciation, amortisation	-$15.1M	-$64.9M	-$7.6M	-$46.5M

USD

Dec 2025

Mar 2026

Jun 2026

Sep 2026

What came in

RevenueTotal revenue

$3.9M

$2.2M

$755.0K

$1.1M

Cost of what it soldCost of revenue

$13.0K

—

Gross profit

$3.9M

$2.1M

$755.0K

$1.1M

What it spent

Research and development

$10.4M

$10.6M

$11.2M

$14.5M

Sales and adminSelling, general and administrative

$4.9M

$5.9M

$6.0M

$5.9M

Total operating expenses

$15.3M

$16.5M

$17.2M

$20.4M

What was left

Operating profitOperating income

-$11.5M

-$14.4M

-$16.5M

-$19.2M

Interest on debtInterest expense

$1.4M

$651.0K

$531.0K

Profit before tax

-$16.5M

-$65.5M

-$8.1M

-$46.5M

Net profitNet income

-$16.5M

-$65.5M

-$8.1M

-$46.5M

EBITDAEarnings before interest, tax, depreciation, amortisation

-$15.1M

-$64.9M

-$7.6M

-$46.5M

Opus Genetics, Inc.

Smart money at a glance

What do analysts expect?

Questions about IRD filings

Smart money on IRD

Questions about IRD filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 28.6% below what analysts expected.

What the street expects next

Previous reports

What it sold, what it cost, what was left.

Price structure

Ask it in Claude or ChatGPT.

Opus Genetics, Inc.

Smart money at a glance

What do analysts expect?

Questions about IRD filings

Smart money on IRD

Questions about IRD filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 28.6% below what analysts expected.

What the street expects next

Previous reports

What it sold, what it cost, what was left.

Price structure

Ask it in Claude or ChatGPT.

Opus Genetics, Inc.

Overview

Questions about IRD filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Opus Genetics, Inc.

Overview

Questions about IRD filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.